The Parkinson’s Progression Markers Initiative (PPMI) is The Michael J. Fox Foundation’s flagship biomarkers study seeking to learn more about Parkinson’s disease. PPMI is made possible by the commitment of a diverse set of over 700 research volunteers. With their help, PPMI has become a groundbreaking clinical study, helping pinpoint biological clues about Parkinson’s to help treat, diagnose and one day cure the disease.
PPMI is currently studying the connection between PD and having a mutation in either the LRRK2 or GBA gene — both are promising targets of PD research. Whether you have PD or not, you may be eligible to receive genetic counseling and testing at no cost to determine if you qualify to participate in PPMI.
Over the past decade, studies of the genetics of Parkinson’s disease have revolutionized the pursuit of a “disease-modifying” treatment — a therapy that can slow or stop the progression of PD. Studying people with Parkinson’s and their families is essential to help researchers identify genetic traits that may contribute to the onset and progression of PD.
To learn about other Parkinson’s clinical trials that are recruiting in your area, visit Fox Trial Finder.